31846-94-3Relevant academic research and scientific papers
Synthesis, X-ray crystal and monoamine oxidase inhibitory activity of 4,6-dihydrobenzo[c]pyrano[2,3-e][1,2]thiazine 5,5-dioxides: In vitro studies and docking analysis
Ahmad, Shakeel,Jalil, Saquib,Zaib, Sumera,Aslam, Sana,Ahmad, Matloob,Rasul, Azhar,Arshad, Muhammad Nadeem,Sultan, Sadia,Hameed, Abdul,Asiri, Abdullah M.,Iqbal, Jamshed
, p. 9 - 22 (2019)
We report the synthesis and biological evaluation of two new series of 2-amino-6-benzyl-4-phenyl-4,6-dihydrobenzo[c]pyrano[2,3-e][1,2]thiazine-3?carbonitrile 5,5-dioxides and 2-amino-6-methyl-4-phenyl-4,6-dihydrobenzo[c]pyrano[2,3-e][1,2]thiazine-3?carbon
Synthesis, characterization, monoamine oxidase inhibition, molecular docking and dynamic simulations of novel 2,1-benzothiazine-2,2-dioxide derivatives
Ahmad, Shakeel,Zaib, Sumera,Jalil, Saquib,Shafiq, Muhammad,Ahmad, Matloob,Sultan, Sadia,Iqbal, Mazhar,Aslam, Sana,Iqbal, Jamshed
, p. 498 - 510 (2018/07/13)
In this research work, we report the synthesis and biological evaluation of two new series of 1-benzyl-4-(benzylidenehydrazono)-3,4-dihydro-1H-benzo[c] [1,2]thiazine 2,2-dioxides and 1-benzyl-4-((1-phenylethylidene)hydrazono)-3,4-dihydro-1H-benzo[c][1,2]t
Gas-phase domino cyclization of phosphonium ylides leading to the total synthesis of Eustifoline D
Aitken, R. Alan,Murray, Lorna
supporting information, p. 4328 - 4332 (2017/10/17)
Six stabilised phosphonium ylides bearing ortho-benzylaminophenyl and cinnamoyl (or a heterocyclic analogue) groups have been prepared and upon flash vacuum pyrolysis at 800 °C were found to undergo cascade cyclization processes to give mainly 3-styrylquinolines but also in some cases ring-fused carbazoles and other fused-ring heterocyclic products. By starting with an appropriate ring-methylated precursor the natural product Eustifoline D was obtained in 19% yield in the pyrolysis in addition to the 3-(2-furylethenyl)quinoline (46%).
CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS
-
Page/Page column 82, (2008/06/13)
The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
Constrained compounds as CGRP-receptor antagonists
-
Page/Page column 46-47, (2008/06/13)
The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
